Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TME2
- Development stage
- Preclinical
- Lead developer
- Pan Cancer T
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
TME2 is an investigational T-cell receptor engineered T-cell (TCR-T) therapy currently in preclinical development by Pan Cancer T. Designed as a pan-cancer therapeutic, TME2 aims to target solid tumors by utilizing engineered T-cells to recognize specific tumor antigens. The program is part of a broader effort to develop next-generation adoptive cell therapies that can effectively navigate and combat the immunosuppressive tumor microenvironment (TME). While the specific target and mechanism of action remain undisclosed by the sponsor, the therapy is intended to provide a new treatment option for various malignant solid tumors.
Beyond the preview
Go deeper on TME2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TME2.